Teva has set out more details of how it plans to improve its profit margins in the wake of an extensive restructuring of the business, as the firm has reported a mixed impact from the COVID-19 pandemic in the first quarter of 2020.
Having at the end of 2019 celebrated the completion of a long-term restructuring plan – with measures that included cutting...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?